CorMedix
CRMD
101 hedge funds and large institutions have $71.4M invested in CorMedix in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 8 closing their positions.
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
10% more funds holding
Funds holding: 92 → 101 (+9)
8% more capital invested
Capital invested by funds: $66.2M → $71.4M (+$5.21M)
2.01% more ownership
Funds ownership: 32.64% → 34.65% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
63% less call options, than puts
Call options by funds: $551K | Put options by funds: $1.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.27M |
| 2 |
BlackRock
New York
|
+$1.2M |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$685K |
| 4 |
State Street
Boston,
Massachusetts
|
+$661K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$601K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.55M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$701K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$555K |
| 4 |
Millennium Management
New York
|
-$293K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$277K |
CRMD Hedge Fund Activity: Q4 2023 in Review
101 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q4 2023, worth a combined $71.4M — up 7.9% from $66.2M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CRMD positions and 8 closed out — a net gain of 9 holders — while 37 added to existing stakes and 20 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.27M. The largest seller was Marshall Wace, cutting an estimated $1.55M.
- 101 institutional investors held CorMedix (CRMD) as of Q4 2023, up from 92 in Q3 2023.
- Funds reported $71.4M of CorMedix stock for Q4 2023, up 7.9% quarter-over-quarter.
- 17 funds opened new CorMedix positions in Q4 2023 and 8 closed out, a net change of +9 holders.
- The largest CorMedix buyer in Q4 2023 was Morgan Stanley, an estimated $1.27M added.
- The largest CorMedix seller in Q4 2023 was Marshall Wace, an estimated $1.55M sold.
Based on aggregated 13F filings for Q4 2023.